Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
20
8
2021
medline:
3
2
2022
entrez:
19
8
2021
Statut:
ppublish
Résumé
The aim of this study was to examine neurocognitive course over time among people with well treated HIV. The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study is an ongoing, prospective, longitudinal, multicenter and multilingual study within the Swiss HIV Cohort Study (SHCS). Participants undergo neuropsychological assessment at baseline and two-yearly follow-up. Seven SHCS centres. Patients aged at least 45 years enrolled in the SHCS with fluency in the local language (French, German or Italian) and agreeing to participate in the NAMACO study: 981 participants at baseline, 720 at 2-year follow-up of whom 644 had complete data sets. Standardized neuropsychological assessment at baseline and 2-year follow-up. Neurocognitive performance using Frascati criteria and mean z-scores. Four participants (of 644, 0.6%) had plasma HIV-1 RNA more than 50 copies/ml; median CD4+ cell count was 660 cells/μl. According to Frascati criteria, 204 participants (31.7%) had neurocognitive impairment (NCI) at baseline. NCI severity in these participants changed little over 2 years and comprehensive models based on Frascati criteria were not feasible. Examining mean z-scores, however, we observed neurocognitive stability or improvement over two years in five of seven neurocognitive domains assessed. Age at least 65 years (P = 0.02) and cognitive complaints (P = 0.004) were associated with neurocognitive decline, while black race (P = 0.01) and dolutegravir treatment (P = 0.002) were associated with improvement. Frascati criteria were less sensitive in measuring NCI change and therefore unsuitable for following neurocognitive course in our cohort of people with well treated HIV. Examining neurocognitive course by mean z-score change, we observed stability or improvement.
Identifiants
pubmed: 34411034
doi: 10.1097/QAD.0000000000003057
pii: 00002030-900000000-96330
pmc: PMC8631148
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2469-2480Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
J Int Neuropsychol Soc. 2004 May;10(3):317-31
pubmed: 15147590
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
BMC Infect Dis. 2011 Dec 28;11:356
pubmed: 22204557
AIDS. 2010 Jun 1;24(9):1243-50
pubmed: 19996937
Neurology. 2011 Apr 19;76(16):1403-9
pubmed: 21502598
Clin Infect Dis. 2015 Feb 1;60(3):473-80
pubmed: 25362201
Clin Infect Dis. 2014 Oct;59(7):1032-7
pubmed: 24944232
Neurology. 2014 Jun 10;82(23):2055-62
pubmed: 24814848
HIV Med. 2020 Jan;21(1):30-42
pubmed: 31589807
PLoS One. 2018 Apr 11;13(4):e0194760
pubmed: 29641619
J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):202-208
pubmed: 29762344
Lancet HIV. 2017 Sep;4(9):e411-e422
pubmed: 28716545
HIV Med. 2017 May;18(5):363-369
pubmed: 27785907
Open Forum Infect Dis. 2019 Jul 08;6(7):ofz277
pubmed: 31304188
Neurology. 2016 Jan 26;86(4):334-40
pubmed: 26718568
AIDS Behav. 2011 Feb;15(2):376-88
pubmed: 21046221
Top HIV Med. 2010 Apr-May;18(2):45-55
pubmed: 20516524
AIDS Patient Care STDS. 2017 Aug;31(8):329-334
pubmed: 28753395
HIV Med. 2020 May;21(5):342-348
pubmed: 31883203
AIDS. 2015 Mar 27;29(6):713-21
pubmed: 25565498
Neurology. 2007 Dec 11;69(24):2213-20
pubmed: 17914066
Neurology. 2010 Dec 7;75(23):2087-96
pubmed: 21135382
J Int Neuropsychol Soc. 2012 Jan;18(1):79-88
pubmed: 22114912
Top HIV Med. 2006 Mar-Apr;14(1):21-6
pubmed: 16641524
HIV Med. 2015 Apr;16 Suppl 1:97-108
pubmed: 25711328
AIDS. 2019 Oct 1;33(12):1863-1870
pubmed: 31259761
Int J Epidemiol. 2010 Oct;39(5):1179-89
pubmed: 19948780
Clin Infect Dis. 2018 Jun 1;66(12):1899-1909
pubmed: 29309532